Payment overview · 2025
General Payments
$281.44
10 reported records · 7 companies
Healthcare provider profile · identity verified
Sherry Leann Mcgraw
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · RICHLANDS, VA · NPI 1962943878
Verified facts
What the public records show
CMS Open Payments records show Sherry Leann Mcgraw received $281.44 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 54.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Relistor by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $152.17 | 54.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.45 | 11.5% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $25.51 | 9.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.28 | 7.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.25 | 6.1% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $16.35 | 5.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.43 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $281.44 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $152.17 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $38.63 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.45 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 511 | 69 |
| Gabapentin | Gabapentin | 500 | 93 |
| Alprazolam | Alprazolam | 304 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 283 | 69 |
| Omeprazole | Omeprazole | 278 | 74 |
| Famotidine | Famotidine | 276 | 75 |
| Lisinopril | Lisinopril | 224 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 219 | 65 |
| Furosemide | Furosemide | 213 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 190 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 54 |
| Losartan Potassium | Losartan Potassium | 171 | 57 |
| Montelukast Sodium | Montelukast Sodium | 168 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 43 |
| Tramadol Hcl | Tramadol Hcl | 156 | 31 |
| Lorazepam | Lorazepam | 133 | 34 |
| Potassium Chloride | Potassium Chloride | 131 | 35 |
| Prednisone | Prednisone | 125 | 70 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 112 | 37 |
| Metformin Hcl | Metformin Hcl | 111 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 32 |
| Ezetimibe | Ezetimibe | 106 | 29 |
| Trazodone Hcl | Trazodone Hcl | 105 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 99 | 14 |
| Ozempic | Semaglutide | 96 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 28 |
| Clonazepam | Clonazepam | 88 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 28 |
| Simvastatin | Simvastatin | 86 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 85 | 33 |
| Allopurinol | Allopurinol | 83 | 21 |
| Pregabalin | Pregabalin | 78 | 15 |
| Meloxicam | Meloxicam | 76 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 23 |
| Glimepiride | Glimepiride | 74 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 18 |
| Ibuprofen | Ibuprofen | 69 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 18 |
| Amoxicillin | Amoxicillin | 67 | 50 |
| Clonidine Hcl | Clonidine Hcl | 66 | 15 |
| Eliquis | Apixaban | 66 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 65 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 15 |
| Ondansetron Odt | Ondansetron | 60 | 16 |
| Cefdinir | Cefdinir | 57 | 48 |
| Fluconazole | Fluconazole | 56 | 26 |
| Mounjaro | Tirzepatide | 56 | 11 |
| Sertraline Hcl | Sertraline Hcl | 56 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 55 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | suppressed |
| Spironolactone | Spironolactone | 54 | 18 |
| Alendronate Sodium | Alendronate Sodium | 52 | 14 |
| Synthroid | Levothyroxine Sodium | 52 | suppressed |
| Azithromycin | Azithromycin | 51 | 40 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | suppressed |
| Temazepam | Temazepam | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 47 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | 15 |
| Carvedilol | Carvedilol | 46 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 45 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 44 | 11 |
| Methylprednisolone | Methylprednisolone | 43 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 16 |
| Buspirone Hcl | Buspirone Hcl | 41 | 11 |
| Diazepam | Diazepam | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | 14 |
| Linzess | Linaclotide | 38 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 24 |
| Levofloxacin | Levofloxacin | 37 | 23 |
| Naproxen | Naproxen | 37 | 13 |
| Promethazine Hcl | Promethazine Hcl | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Atenolol | Atenolol | 36 | 12 |
| Sucralfate | Sucralfate | 36 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 35 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 21 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 15 |
| Methocarbamol | Methocarbamol | 28 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 23 |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Nystatin | Nystatin | 27 | 16 |
| Cephalexin | Cephalexin | 26 | 15 |
| Estradiol | Estradiol | 26 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Mupirocin | Mupirocin | 23 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 11 |
| Relistor | Methylnaltrexone Bromide | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Lactulose | Lactulose | 17 | 11 |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 15 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Budesonide Ec | Budesonide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Promethegan | Promethazine Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Veozah | Fezolinetant | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $281.44 · 10 records | ABBVIE INC. | FANAPT, FARXIGA, REXULTI, TRINTELLIX, VRAYLAR, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error